Mean AUC 0-120 (range 569.7 to 628.6 min*ng/ml for BIDI ® Stick ENDS and 747.1 min*ng/ml for UB cigarettes) and median T max 0–120 (range 5-7 min for all BIDI ® Stick ENDS and UB cigarettes) values were also not significantly different between BIDI ® Stick ENDS and UB cigarettes, while subjective effects measures were also similar between BIDI ® Stick ENDS and UB cigarettes. Mean plasma nicotine C max 0–120 was not significantly different between BIDI ® Stick ENDS with any flavour (range 15.3 ng/ml for BIDI ® Stick Winter to 17.6 ng/ml for BIDI ® Stick Classic) and UB cigarettes (16.2 ng/ml). Blood samples were collected at various time points and subjective effects questionnaires were administered. During each of eight study visits, 18 volunteer smoker subjects randomly used one of either their usual brand (UB) of cigarette, a BIDI ® Stick ENDS, or a comparator ENDS (JUUL 59 mg/ml nicotine with Virginia Tobacco flavour), during both controlled (10 puffs, 30 s apart) and ad libitum (60 min) puffing sessions. In this study, we assessed nicotine pharmacokinetics and subjective effects of 6 flavour variants of BIDI ® Stick ENDS in adult smokers, compared to cigarettes and a comparator ENDS product. The BIDI ® Stick is a disposable ENDS product which contains 59 mg/ml nicotine benzoate salt and various flavours.

Subjective effects data also strongly contribute to this understanding. Nicotine pharmacokinetic assessments of electronic nicotine delivery systems (ENDS) are crucial to understand their ability to provide an alternative to cigarette smoking.

Max 120 cigarettes